PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28781637-0	2017	Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1alpha/vascular endothelial growth factor signaling pathway in human lung cancer cells.	Niclosamide	0-11	vascular endothelial growth factor A	Homo sapiens	106-140	
29251334-7	2018	In this study, we found that niclosamide could not only inhibit proliferation and promote apoptosis of oral cancer cells, but also inhibited VM formation in vitro and in vivo through downregulation of the expression of VM-related genes VEGFA, MMP2, ROCK1 and Cdc42.	Niclosamide	29-40	vascular endothelial growth factor A	Homo sapiens	236-241	
28781637-5	2017	The present study demonstrated that niclosamide enhanced the effect of irradiation by inhibiting the hypoxia-inducible factor-1alpha/vascular endothelial growth factor signaling pathway.	Niclosamide	36-47	vascular endothelial growth factor A	Homo sapiens	133-167	
26499405-10	2015	Niclosamide also suppresses VEGF-induced angiogenesis in vivo.Niclosamide attenuated IKK-mediated activation of NF-kappaB pathway in TNFalpha-induced endothelial cells.	Niclosamide	0-11	vascular endothelial growth factor A	Homo sapiens	28-32	
26499405-10	2015	Niclosamide also suppresses VEGF-induced angiogenesis in vivo.Niclosamide attenuated IKK-mediated activation of NF-kappaB pathway in TNFalpha-induced endothelial cells.	Niclosamide	62-73	vascular endothelial growth factor A	Homo sapiens	28-32	
26499405-11	2015	Niclosamide also suppresses VEGF-induced endothelial VEGFR2 activation and downstream P-AKT, P-mTOR and P-p70S6K.	Niclosamide	0-11	vascular endothelial growth factor A	Homo sapiens	28-32